1. Background
Multiple myeloma (MM) is the second most common hematologic malignancy, accounting for 1% of all cancers globally in 2016 [ 1 ]. MM mainly occurs in older people, with a median age of 66–70 years at the time of diagnosis [ 1 ]. Age demography significantly contributes to MM progression and regimen design [ 2 , 3 ]. Survival rates are higher in younger people, partially due to the feasibility of autologous stem cell transplant (ASCT) and better drug tolerability during adjuvant therapy to ASCT or non-transplant systemic therapy. Nevertheless, overall survival rates have risen significantly over the past decades [ 4 , 5 ], with a five-year survival rate of 53.9% between 2010 and 2016 in the United States (US) [ 5 ]. Improved outcomes resulted from a significant increase of the use of novel therapies, including proteasome inhibitors and immunomodulatory drugs (IMiDs), which increased from 8.7% in 2000 to 61.3% in 2014 in US patients [ 6 ]. Additionally, the introduction of low-dose continuous therapy and maintenance therapy schemes post-ASCT or high-dose induction therapy also contributed to improved clinical outcomes, mainly through palliating adverse effects to increase drug tolerability, especially in weak elderly patients [ 7 ]. Aside from improvements in therapeutic design, novel drugs are designed to target specific molecular mechanisms involved in MM, especially the nuclear factor kappa B (NF-κB) signaling pathway [ 8 , 9 , 10 ], which is described in the following context.
2. Multiple Myeloma and NF-κB Signaling
Myeloma, also known as plasma cell myeloma, is the accumulation of malignant plasma cells in the bone marrow. Initially, in the asymptomatic phase (known as smoldering myeloma), myeloma cells produce abnormally substantial amounts of monoclonal proteins (M-proteins) that are released to the blood stream. As the disease progresses to the symptomatic phase, known as MM, the myeloma cells harness the bone marrow microenvironment to promote growth and invasion. MM progression leads to bone destruction, hypercalcemia and renal insufficiency, and may result in patient lethality.
MM is linked to the frequent onset of hyperploidy, chromosomal aberrations, genetic mutations and epigenetic transformations. Among these anomalies, hyperploidy is most prevalent, contributing to nearly half of all MM cases [ 11 ]. In non-hyperploid MM, chromosomal aberrations at the B cell class switching gene locus IGH frequently occur, leading to aberrant production of M-proteins in MM patients [ 12 , 13 ]. Aside from chromosomal changes, genetic mutations common in cancers frequently occur in MM too, e.g., the oncogenic KRAS and NRAS transformations and loss-of-function TP53 mutations [ 11 , 14 , 15 , 16 ]. Some genetic modifications are more MM-specific and contribute to hyperactive NF-κB signaling. These include the amplification or rearrangement of NIK , LTBR , TACI , NFKB1 , NFKB2 and CD40 genes, as well as deletion or loss-of-function mutations in genes like CYLD , BIRC2/BIRC3 ( cIAP1/cIAP2 ), TRAF2 and TRAF3 [ 17 ]. On the other hand, MM progression displays distinct epigenetic landscape changes. For example, extensive DNA hypomethylation in non-CpG islands occurs during the transition from monoclonal gammopathy of undetermined significance to the myeloma stage [ 18 ]. Moreover, hypermethylation of a subset of transcription factors, e.g., FOXD2 , GATA4 , RUNX2 , and cell cycle-related genes, e.g., CDKN2B , potentially remodels cellular processes to promote tumorigenesis [ 18 ]. Furthermore, MM development is supported by the promoter methylation of the P53 gene, which is sustained by the NF-κB-regulated cytokine interleukin-6 (IL-6) [ 19 ]. Aside from DNA methylation, histone modifications such as acetylation and methylation also significantly alter the epigenetic landscape and drug response of MM [ 20 ]. For instance, overexpression of the histone methyltransferase gene EZH2 that frequently occurs in MM may be induced by hyperactive non-canonical NF-κB signaling [ 21 ]. Inhibition of EZH2 sensitizes MM to bortezomib treatment in vivo, through cooperative MYC suppression and inhibition of H3K27 trimethylation to regulate genes involved in B cell metabolism and antibody production [ 22 , 23 ]. NF-κB gene mutations are known to be the most prevalent in MM among all human cancers [ 14 , 15 , 17 , 24 , 25 ], and plays a pivotal role in anti-cancer therapy and drug resistance [ 26 , 27 , 28 , 29 ].
NF-κB refers to a family of transcription factors that form homo- and hetero-dimers within the family, as well as with other transcription factors [ 30 ]. NF-κB signaling is classified into the canonical and non-canonical pathways that are represented by the transcriptional protein complexes of p50/RelA and p52/RelB, respectively [ 31 ]. These two pathways are activated by distinct membrane receptors that respond to extracellular ligands like tumor necrosis factor α (TNFα), interleukin-1 (IL-1), receptor activator of NF-κB ligand (RANKL), and so on ( Figure 1 ). In canonical NF-κB signaling, receptor activation leads to formation of the TRAF2-TRAF5-TRAF6 complex, which activates TAK1 kinase to phosphorylate the complex of IKKα, IKKβ and NEMO. IKK complex phosphorylation subsequently triggers the degradation of IκB to release the p105 protein for proteasomal processing to the p50 protein. Consequently, the p50/RelA complex translocates to the nucleus and initiates transcription. Non-canonical NF-κB signaling involves the TRAF2-TRAF3-TRAF6 complex, which activates the NIK kinase to phosphorylate the IKKα kinase. Phosphorylated IKKα then triggers proteasomal processing of p100 to p52 for transcriptional activation. Although the canonical and non-canonical pathways have variant triggering signals and downstream targets, both pathways are involved in MM pathogenesis and progression [ 15 , 24 , 25 ].
NF-κB signaling plays a pivotal role in promoting cancer growth, angiogenesis and tumor-microenvironment crosstalk, which mainly involves the production of pro-inflammatory cytokines, inflammation mediators, cell adhesion molecules, among others, to establish a favorable tumor microenvironment for MM tumorigenesis and disease progression. Non-canonical NF-κB signaling is also a key determinant of other oncogenic drivers, such as telomerase and telomeric proteins, which are commonly deregulated in cancers [ 32 , 33 , 34 , 35 ]. NF-κB signaling, in combination with other potent transcription factors such as STAT3, also plays important roles in regulating apoptosis and polarization of immune subtypes, which contribute to a pro-tumoral microenvironment [ 36 , 37 ]. Hence, many first-line anti-MM drugs have an indirect impact on the NF-κB signaling pathway ( Figure 1 ). For instance, bortezomib is a reversible inhibitor of the 26S proteasome [ 38 ] and thus prevents the proteasomal cleavage of NF-κB proteins and the IκB protein to inhibit gene transcription activation. The insult of bortezomib on MM cells is further enhanced by the fact that the proteasome is overloaded by excessive M-protein production in myeloma cells. On the other hand, the corticosteroid dexamethasone induces inhibitor of κB (IκB) protein synthesis to inhibit NF-κB signaling [ 39 ]. Another first-line therapy drug, the IMiD lenalidomide, diminishes sustained RelA binding to open chromatin by inhibiting the Ikaros proteins Ikzf1 and Ikzf3 [ 40 , 41 , 42 ]. Co-administration of lenalidomide and dexamethasone suppresses interleukin-2 (IL-2), immunoglobin M (IgM) and immunoglobin G (IgG) production, hence reducing the protein load of MM patients [ 43 ]. In recent years, immunotherapy using antibodies and chimeric antigen receptor T (CAR-T) cells against specific NF-κB signaling receptors has gained more attention. For example, antibodies against B cell-activating factor (BAFF) inactivate non-canonical NF-κB signaling in MM cells [ 44 , 45 ]. Clinical trials are ongoing, so it is still too early to conclude whether any of these strategies works.
In addition to intracellular NF-κB hyperactivation, MM cells also manipulate NF-κB signaling in the bone marrow microenvironment to promote cancer growth and invasion ( Figure 2 ). On the one hand, myeloma cells hijack stromal cells to secrete cytokines, such as interleukin-6 (IL-6), receptor activator of NF-κB ligand (RANKL) and vascular endothelial growth factor (VEGF), to promote cancer proliferation and angiogenesis [ 46 ]. On the other hand, myeloma cells secrete Dickkopf-1 (Dkk1) and macrophage inflammatory factor 1α (MIP-1α) to inhibit osteoblast differentiation to block new bone formation, and activate osteoclasts to promote osteolysis [ 47 , 48 ]. In late-stage MM patients, the myeloma cells acquire additional genetic abnormalities that lead to reduced dependency on the microenvironment (e.g., P53 mutation), increased drug resistance and increased aggressiveness of the clone (e.g., 1q21 amplification and CKS1B overexpression) [ 49 ]. Hence, therapies against both MM cells and microenvironment control, such as daratumab, an antibody drug against CD38 that induces antibody-dependent cytotoxic events in CD38-expressing cancer cells and complement-dependent cytotoxicity [ 50 , 51 , 52 ], show success in MM treatment [ 53 ].
Even though receptor-/ligand-specific antibodies can target NF-κB signaling with high specificity, the diverse NF-κB signals in MM cells and their microenvironment limit the application of these therapies to treat MM effectively in vivo. Tumor evolution also contributes to altering pathways to develop drug resistance. Hence, directly targeting the molecular machinery of NF-κB signaling remains crucial. Until now, no specific NF-κB inhibitor has been approved for treating MM. We will discuss the challenges of developing specific NF-κB inhibitors for MM treatment.
3. NF-κB Signaling: The Rose with Thorns in MM Treatment
Even though NF-κB signaling plays a critical role in MM, specifically targeting this signaling pathway proves to be more difficult than previously thought.
The foremost hurdle is drug safety. NF-κB signaling plays a key role in innate immunity and inflammation. Constitutive inactivation of NF-κB signaling silences the immune system, subsequently rendering patients susceptible to infections. Population-based studies have pointed out that MM patients displayed a seven-fold higher risk of bacterial infection and a 10-fold higher risk of viral infections as compared to randomized control individuals, resulting in a stunning 22% death rate among MM patients at one-year follow-up [ 54 ]. It is noteworthy that transplanted patients displayed a broader spectrum of infection [ 55 ], where infection rate may be reduced by combined IMiD therapy [ 56 ], due to the fact that immunosuppressive drugs are administered to prevent graft-versus-host defense. On the other hand, bortezomib-based therapy is associated with a higher risk of severe infection in various studies [ 56 , 57 , 58 ], possibly through inhibition of both canonical and non-canonical NF-κB pathways. Hence, it is hypothesized that targeting of one NF-κB pathway may be safer than inactivating both NF-κB signaling pathways. Nevertheless, trials of many IKKβ inhibitors showed severe adverse effects [ 59 ], even though non-canonical NF-κB signaling is hypothesized to be unaffected. In contrast, the anti-RANK antibody denosumab, which is recommended as adjuvant therapy to MM patients to alleviate hypercalcemia due to hyperactive osteoclasts [ 60 ], produces little toxicity but cannot treat MM because of its narrow-spectrum inhibition of RANK-mediated non-canonical NF-κB signaling. Hence, striking the right balance between drug safety and treatment efficiency remains challenging.
Secondly, the context-specific and spatio-temporal regulation of NF-κB signaling complicates therapeutic design. This complexity is further complicated by the interplay between cancer and its immune microenvironment [ 26 , 46 , 61 , 62 ]. For example, the non-steroidal anti-inflammatory drugs (NSAIDs) (e.g., aspirin, sulindac and tolfenamic acid) that target the COX-1/2 genes may suppress NF-κB signaling during short-term administration but activate NF-κB signaling after prolonged treatment [ 59 ].
Thirdly, selectivity remains a critical issue. For instance, several IKKβ inhibitors exhibit off-target effects, whereas others display high selectivity toward IKKβ and loss of inhibition through IKKα [ 59 ]. In this regard, combined treatment may offer hope for highly selective inhibitors, but this also requires more consideration of the treatment burden on patients, especially when many MM patients are old and weak. Nevertheless, high selectivity suffers from poor treatment efficiency. For instance, the anti-BAFF antibody tabalumab, which specifically inhibits non-canonical NF-κB signaling, failed to improve outcomes in MM patients in a phase II trial in which it was combined with bortezomib and dexamethasone [ 63 ].
Lastly, the lack of structural information hampers rational drug design, although solving the structure does not guarantee success either. For example, structure of the NF-κB inducing kinase (NIK) has been solved [ 64 ], but the NIK inhibitors AM-0216 and AM-0561 failed due to poor pharmacokinetics in vivo, even though they displayed high NIK binding affinity and NIK -dependent cytotoxicity in vitro [ 65 ]. On the contrary, a peptide mimetic of the NF-κB essential modulator (NEMO) binding domain that blocks IKK complex formation [ 66 ] made its way to clinical trials in dogs for treating diffuse large B cell lymphoma (DLBCL) and soft tissue sarcoma (STS) [ 67 ], but no clinical trial has been reported to treat humans. Other molecular targets might lack specific inhibitors after solving the structure [ 68 ]. Consequently, no specific NF-κB inhibitor has been successfully developed to treat MM until now.
4. MM Therapy: A Steep Road to Success
MM therapy mainly involves stem cell transplant and systemic drug therapy with occasional use of radiotherapy for plasmacytomas ( Figure 3 ). ASCT is an important treatment modality for MM patients, whereas allogeneic stem cell transplant is suggested for high-risk patients with complex karyotypes [ 69 ]. However, allogeneic stem cell transplant is still rarely used in MM patients because of high rates of treatment-related mortality. Furthermore, stem cell transplant is often infeasible because of the frailty of MM patients, who are mostly elderly, aged 65 and above. Hence, systemic drug therapy remains an indispensable approach for MM treatment. Similar to many other cancers, MM is often treated by a combination of drugs.
Among these drugs, bortezomib is the most frequently used drug for MM treatment. Bortezomib is commonly paired with IMiDs such as lenalidomide and thalidomide, or alkylating agents such as melphalan, cyclophosphamide and dexamethasone. Dexamethasone, lenalidomide and prednisone all exhibit anti-inflammatory responses. On the other hand, melphalan is a DNA alkylating drug that has been used to treat MM since the 1950s [ 70 ]. Among all these drugs, melphalan and prednisone are the oldest drugs used in MM treatment [ 71 ]. It is noteworthy that combination therapy is usually used for MM treatment, often as a means of exploiting drugs with different mechanisms of action.
Existing anti-MM drugs target a diverse array of molecular pathways ( Table 1 ). Analysis of the recommended drugs along the lines of therapy, together with those undergoing clinical trials, displays an interesting trend ( Figure 4 ). Briefly, anti-inflammatory drugs take a central role in MM therapy and are applied to both standard therapy and maintenance therapy for MM patients, given the pivotal role of NF-κB and inflammation in MM progression. Next, the impact of protein secretion load in myeloma cells and the resultant endoplasmic reticulum stress make the cells vulnerable to inhibition of the proteolysis pathways. Therefore, proteasome inhibitors, including bortezomib and carfilzomib, often make up a base for different combination therapies. Aside from the MM-specific mechanisms, drugs that disrupt DNA and RNA synthesis, promote cell death and inhibit angiogenesis are frequently applied to MM treatment too. However, the most intriguing part is the increasing trend of other therapeutic mechanisms in drugs undergoing clinical trials or in research. The common mechanism of these drugs is the specific targeting of certain molecules or molecular pathways, especially NF-κB signaling. For instance, selinexor blocks exportin to retain NF-κB in the nucleus [ 72 , 73 ].
Targeting NF-κB signaling takes the center stage of anti-MM drug development. For instance, antibodies against CD38, CS1, BAFF and BCMA showed success in MM treatment [ 50 , 53 , 74 , 75 ]. Parallel tests were conducted using chimeric antigen receptor T (CAR-T) cells [ 76 , 77 , 78 ], but relapse became a major concern [ 79 ]. In addition, antibodies and peptides against the programmed cell death 1 (PD-1) protein and its ligand PD-L1 are also heavily investigated [ 80 ], where PD-L1 can be induced by canonical NF-κB signaling [ 81 ]. Development of IKK inhibitors persists [ 59 ], whereas development of NIK inhibitors is also ongoing [ 82 , 83 ]. Recently, a novel NIK inhibitor called Cpd33 is reported to inhibit RANKL-induced osteoclastogenesis in an ovariectomized mouse model [ 84 ]. Oral administration of another NIK inhibitor XT2 in mice relieved toxin-induced liver inflammation [ 85 ]. These inhibitors may be tested in MM mouse models in the future. Progress is also made to disrupt NF-κB-mediated crosstalk between the tumor and its microenvironment. For example, an antibody against Dkk1 is proposed to alleviate osteolysis [ 86 ].
5. Future Direction: Biomarker-Guided Targeted Therapy
The first paradigm shift in MM treatment occurred in early 2000s with the introduction of the first-in-class proteasome inhibitor bortezomib [ 71 ]. Research on the correlation between proteasome load and degradative capacity on the sensitivity of MM cells toward bortezomib was conducted [ 87 ], suggesting that the levels of M-proteins and proteasome expression can be biomarkers for proteasome inhibitor sensitivity. This incidence marks the start of evidence-based therapeutic design for MM treatment. However, even though bortezomib is highly effective, its severe neurotoxicity is often intolerable, leading to drop-offs in many studies [ 88 ]. This subsequently led to exploration of the oral alternative ixazomib, which exhibits lower neurotoxicity [ 89 ]. Additionally, second generation proteasome inhibitors with different chemical moieties were developed to improve outcomes and reduce adverse reactions. For instance, carfilzomib showed a better response than bortezomib in refractory MM [ 90 , 91 , 92 ]; its major adverse effects on the cardiac system also occurred in fewer patients [ 93 ]. These protocols have paved the way for more precise regimens for application to different patient subgroups.
Recently, Shin, et al. identified lymphocyte cytosolic protein 1 ( LCP1 ) gene as a novel NF-κB target in TRAF3 or NIK mutant MM cells [ 94 ] ( Figure 5 ). TRAF3 loss induces constitutively active NIK [ 95 , 96 ], which frequently occurs in MM patients [ 8 , 14 , 17 ]. B cell-specific TRAF3 -/- mice developed MM and peripheral B cell hyperplasia [ 97 , 98 , 99 , 100 ].
LCP1 encodes for the L-plastin protein, which is required for sealing ring formation in osteoclasts [ 101 ], but not in bone formation by osteoblasts in vitro [ 102 ]. Secreted L-plastin by breast cancer cells mediates metastatic osteolysis in mice [ 103 ]. Despite its osteolytic function, L-plastin contributes to metastasis of breast cancer, melanoma and colon cancer [ 103 , 104 , 105 , 106 , 107 , 108 , 109 ]. Studies also reported that L-plastin is responsible for disease progression of bladder and kidney cancer [ 110 , 111 ], and homing of chronic lymphocytic leukemia (CLL) to bone marrow [ 112 ]. Analysis of transcriptomic data showed that LCP1 overexpression is significantly correlated with poor overall and progression-free survival in MM patients [ 94 ].
L-plastin not only serves as a prognostic biomarker, but may also serve as a therapeutic target. For instance, radiotherapy represses exosomal release of L-plastin in both the tumor and its niche, producing radiation-induced bystander effects and enhance outcomes [ 113 ]. Inhibition of L-plastin Ser5 phosphorylation re-sensitizes resistant MM cells to IMiDs and proteasome inhibitors [ 114 ]. Collectively, these data suggest that inhibiting L-plastin provides an alternative route to treating MM, specifically in TRAF3 -mutant MM patients. In this regard, peptide inhibitors against L-plastin that inhibit osteoclast activity [ 102 , 115 ] might be tested. Alternatively, NIK inhibitors under development [ 82 , 83 ], or shown to repress inflammation in other mouse models [ 84 , 85 ], may be tested in MM mouse models too.
The revelation of LCP1′ s involvement in TRAF3 -mutant MM has led to deeper investigation of the role of calcium signaling in MM development and progression. It has been reported that calcium signaling activates NF-κB in B cells [ 116 ]. For instance, B cell receptor (BCR) activation stimulates store-operated calcium entry (SOCE) to induce NFKB2 expression [ 117 ], which encodes for p100 that is processed into p52 during non-canonical NF-κB activation. On the other hand, calcineurin A associates with TRAF3 and NIK to inhibit LTβR-mediated NIK activity and TWEAK-mediated p100 processing in fibroblasts [ 118 ]. Simultaneously, the calcineurin A-specific inhibitors cyclosporin A and FK506 inhibit IgM-induced B cell activation and trigger cell death [ 119 ]. Taken together, targeting L-plastin and calcium-dependent NF-κB activation may be favorable for MM therapy.
Massive chromosomal aberrations are a key feature of MM. Nearly half of MM tumors are hyperdiploid, usually comprising multiple copies of chromosomes 3, 5, 7, 9, 11, 15, 19 and 21 [ 11 ], whereas non-hyperdiploid MM tumors usually contain IGH translocations that do not involve c-myc [ 12 , 13 ]. This finding led to the proposal of patient risk group stratification based on molecular signatures of MM [ 11 ]. However, cytogenetic analysis of all known mutations might be unaffordable for the less-privileged, so resource-stratified guidelines are proposed to circumvent the cost issue [ 120 ]. In order to carry out patient risk group stratification, genetic test was suggested to be mandated as a routine clinical test for MM patients and subsequent clinical trials in 2009 [ 121 ]. Cytogenetic analysis is exploited to indicate allelic mutations relevant to regimen design. For example, homozygous carriers of the NFKB1 -94insATTG polymorphism were retrospectively demonstrated to benefit more from bortezomib treatment than MM patients carrying the deletion allele [ 122 ]. Bortezomib also exhibits a good response in del17p but not t (4;14) patients and those with 1q21 gain, although its combination with lenalidomide and dexamethasone is promising in del17p, del1p, t (4;14), and t(14;16) patients [ 7 ]. Venetoclax is highly effective in t (11;14) MM patients [ 123 ]. Furthermore, epigenetic changes have been correlated to certain cytogenetic subgroups. For example, extensive DNA hypomethylation is correlated to MM subgroups of hyperploidy, t (4;14), t (11;14), and t (14;16) translocations, but not the del1p, gain 1q, del13q, del16q, del17p and del22q subgroups [ 18 ]. Of note, t (4;14) translocation upregulates the histone methyltransferase multiple myeloma SET domain protein (MMSET) [ 124 ] and inhibition of MMSET activity inhibits MM cell proliferation in vitro [ 125 ]. Nevertheless, more research is needed to elucidate the correlation between different karyotypes and drug sensitivity.
Lastly, drugs to delay MM progression and prevent or re-sensitize MM to treatment are being investigated. For example, an antibody against IL-6 has been tried in smoldering myeloma patients to delay MM progression [ 126 ]. In addition, a potent multi-drug resistance modulator, valspodar, has been investigated to circumvent decreased drug deposition due to P-glycoprotein overexpression in response to therapy [ 127 ], but failed because of unimproved treatment outcomes and increased toxicity [ 128 ]. In contrast, nelfinavir sensitizes MM to overcome proteasome inhibitor resistance through modulating TCF11/Nrf1-mediated proteasome recovery [ 129 ]. Hence, drug development is striving incessantly to overcome the ever-evolving forms of drug resistance.
In addition to treatment efficacy, the tendency to trigger secondary neoplasm development is another key factor to consider during development of novel anti-MM drugs. Early small cohort studies showed that DNA alkylating drugs might possess a higher tendency to induce secondary neoplasms [ 130 , 131 , 132 ]. However, more recent study using a 403-patient cohort suggested that the therapeutic mechanism exhibited an insignificant impact; instead, complex karyotypes are largely correlated to the risk of developing secondary neoplasms [ 133 ]. Nevertheless, the skewed tendency of developing myelodysplastic syndrome (MDS) [ 130 ] warrants deeper investigation into therapy-related secondary neoplasms.
6. Conclusions
MM therapy has come a long way, evolving from the miscellaneous application of rhubarb and orange peel to the anti-proliferative melphalan and anti-inflammatory prednisone, to the first-in-class proteasome inhibitor bortezomib [ 71 ]. History has shown that MM treatment strategies evolved with our understanding of the molecular mechanism of MM progression. In this era of precision medicine, evidence-based therapeutic design has become the golden rule for regimen design. Regimen design considers factors like patient characteristics, therapeutic efficacy, working principle and adverse effects, among many others, from the scientific perspective. From the ethical point of view, treatment burden, quality of life and healthcare cost have received more attention in recent years. In parallel to treatment, diagnostic tests to identify biomarkers and predict treatment outcomes are routinely conducted in some countries. We predict that biomarker-guided targeted therapy will expand as our knowledge grows and continues to evolve in the next decade.
Author Contributions
A.H.-H.W. and E.M.S. contributed to literature search and data collection. A.H.-H.W., E.M.S., V.T. and W.-J.C. discussed the data analysis and interpretation. A.H.-H.W. prepared the figures. A.H.-H.W., E.M.S. and W.-J.C. prepared the manuscript. All authors have read and agreed to the published version of the manuscript.
Funding
AW Medical Company Limited received startup funding from the University Development Fund of University of Macau, Macau.
Conflicts of Interest
The authors declare no conflict of interest.
References
1. Kazandjian D. Multiple myeloma epidemiology and survival: A unique malignancy Seminars in Oncology WB Saunders Philadelphia, PA, USA 2016 676 681 10.1053/j.seminoncol.2016.11.004 PMC5283695 28061985
2. Palumbo A. Bringhen S. Ludwig H. Dimopoulos M.A. Bladé J. Mateos M.V. Rosiñol L. Boccadoro M. Cavo M. Lokhorst H. Personalized therapy in multiple myeloma according to patient age and vulnerability: A report of the European Myeloma Network (EMN) Blood 2011 118 4519 4529 10.1182/blood-2011-06-358812 21841166
3. Palumbo A. Anderson K. Multiple myeloma N. Engl. J. Med. 2011 364 1046 1060 10.1056/NEJMra1011442 21410373
4. Thorsteinsdottir S. Dickman P.W. Landgren O. Blimark C. Hultcrantz M. Turesson I. Björkholm M. Kristinsson S.Y. Dramatically improved survival in multiple myeloma patients in the recent decade: Results from a Swedish population-based study Haematologica 2018 103 e412 e415 10.3324/haematol.2017.183475 29567776 PMC6119139
5. Howlader N. Noone A.M. Krapcho M. Miller D. Brest A. Yu M. Ruhl J. Tatalovich Z. Mariotto A. Lewis D.R. SEER Cancer Statistics Review (1975–2017) Bethesda 2020 Available online: https://seer.cancer.gov/csr/1975_2017/ (accessed on 3 May 2020)
6. Fonseca R. Abouzaid S. Bonafede M. Cai Q. Parikh K. Cosler L. Richardson P. Trends in overall survival and costs of multiple myeloma, 2000–2014 Leukemia 2017 31 1915 1921 10.1038/leu.2016.380 28008176 PMC5596206
7. Dimopoulos M.A. Jakubowiak A.J. McCarthy P.L. Orlowski R.Z. Attal M. Bladé J. Goldschmidt H. Weisel K.C. Ramasamy K. Zweegman S. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma Blood Cancer J. 2020 10 17 10.1038/s41408-020-0273-x 32054831 PMC7018731
8. Cildir G. Low K.C. Tergaonkar V. Noncanonical NF-κB Signaling in Health and Disease Trends Mol. Med. 2016 22 414 429 10.1016/j.molmed.2016.03.002 27068135
9. Puar Y.R. Shanmugam M.K. Fan L. Arfuso F. Sethi G. Tergaonkar V. Evidence for the involvement of the master transcription factor NF-κB in cancer initiation and progression Biomedicines 2018 6 82 10.3390/biomedicines6030082 PMC6163404 30060453
10. Chew C.L. Conos S.A. Unal B. Tergaonkar V. Noncoding RNAs: Master Regulators of Inflammatory Signaling Trends Mol. Med. 2018 24 66 84 10.1016/j.molmed.2017.11.003 29246760
11. Chesi M. Bergsagel P.L. Molecular pathogenesis of multiple myeloma: Basic and clinical updates Int. J. Hematol. 2013 97 313 323 10.1007/s12185-013-1291-2 23456262 PMC3962846
12. Bergsagel P.L. Nardini E. Brents L. Chesi M. Kuehl W.M. IgH translocations in multiple myeloma: A nearly universal event that rarely involves c-myc Current Topics in Microbiology and Immunology Springer Berlin/Heidelberg, Germany 1997 283 287 10.1007/978-3-642-60801-8_30 9308253
13. Fonseca R. Debes-Marun C.S. Picken E.B. Dewald G.W. Bryant S.C. Winkler J.M. Blood E. Oken M. Santana-Dávila R. González-Paz N. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma Blood 2003 102 2562 2567 10.1182/blood-2003-02-0493 12805059
14. Lohr J.G. Stojanov P. Carter S.L. Cruz-Gordillo P. Lawrence M.S. Auclair D. Sougnez C. Knoechel B. Gould J. Saksena G. Widespread genetic heterogeneity in multiple myeloma: Implications for targeted therapy Cancer Cell 2014 25 91 101 10.1016/j.ccr.2013.12.015 24434212 PMC4241387
15. Demchenko Y.N. Michael Kuehl W. A critical role for the NFκB pathway in multiple myeloma Oncotarget 2010 1 59 68 10.18632/oncotarget.109 20890394 PMC2947827
16. Flynt E. Bisht K. Sridharan V. Ortiz M. Towfic F. Thakurta A. Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma Cells 2020 9 287 10.3390/cells9020287 PMC7072230 31991614
17. Keats J.J. Fonseca R. Chesi M. Schop R. Baker A. Chng W.-J. Van Wier S. Tiedemann R. Shi C.-X. Sebag M. Promiscuous Mutations Activate the Noncanonical NF-κB Pathway in Multiple Myeloma Cancer Cell 2007 12 131 144 10.1016/j.ccr.2007.07.003 17692805 PMC2083698
18. Walker B.A. Wardell C.P. Chiecchio L. Smith E.M. Boyd K. Neri A. Davies F.E. Ross F.M. Morgan G.J. Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma Blood 2011 117 553 562 10.1182/blood-2010-04-279539 20944071
19. Hodge D.R. Peng B. Cherry J.C. Hurt E.M. Fox S.D. Kelley J.A. Munroe D.J. Farrar W.L. Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation Cancer Res. 2005 65 4673 4682 10.1158/0008-5472.CAN-04-3589 15930285
20. De Smedt E. Lui H. Maes K. De Veirman K. Menu E. Vanderkerken K. De Bruyne E. The epigenome in multiple myeloma: Impact on tumor cell plasticity and drug response Front. Oncol. 2018 8 566 10.3389/fonc.2018.00566 30619733 PMC6297718
21. Iannetti A. Ledoux A.C. Tudhope S.J. Sellier H. Zhao B. Mowla S. Moore A. Hummerich H. Gewurz B.E. Cockell S.J. Regulation of p53 and Rb Links the Alternative NF-κB Pathway to EZH2 Expression and Cell Senescence PLoS Genet. 2014 10 e1004642 10.1371/journal.pgen.1004642 25255445 PMC4177746
22. Rizq O. Mimura N. Oshima M. Saraya A. Koide S. Kato Y. Aoyama K. Nakajima-Takagi Y. Wang C. Chiba T. Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition Clin. Cancer Res. 2017 23 4817 4830 10.1158/1078-0432.CCR-16-2735 28490465 PMC5562278
23. Guo M. Price M.J. Patterson D.G. Barwick B.G. Haines R.R. Kania A.K. Bradley J.E. Randall T.D. Boss J.M. Scharer C.D. EZH2 Represses the B Cell Transcriptional Program and Regulates Antibody-Secreting Cell Metabolism and Antibody Production J. Immunol. 2018 200 1039 1052 10.4049/jimmunol.1701470 29288200 PMC5780247
24. Annunziata C.M. Davis R.E. Demchenko Y. Bellamy W. Gabrea A. Zhan F. Lenz G. Hanamura I. Wright G. Xiao W. Frequent Engagement of the Classical and Alternative NF-κB Pathways by Diverse Genetic Abnormalities in Multiple Myeloma Cancer Cell 2007 12 115 130 10.1016/j.ccr.2007.07.004 17692804 PMC2730509
25. Demchenko Y.N. Glebov O.K. Zingone A. Keats J.J. Leif Bergsagel P. Michael Kuehl W. Classical and/or alternative NF-κB pathway activation in multiple myeloma Blood 2010 115 3541 3552 10.1182/blood-2009-09-243535 20053756 PMC2867265
26. Pires B.R.B. Silva R.C.M.C. Ferreira G.M. Abdelhay E. NF-kappaB: Two sides of the same coin Genes 2018 9 24 10.3390/genes9010024 29315242 PMC5793177
27. Eluard B. Thieblemont C. Baud V. NF-κB in the New Era of Cancer Therapy Trends Cancer 2020 6 677 687 10.1016/j.trecan.2020.04.003 32409139
28. Dehghanifard A. Kaviani S. Abroun S. Mehdizadeh M. Saiedi S. Maali A. Ghaffari S. Azad M. Various Signaling Pathways in Multiple Myeloma Cells and Effects of Treatment on These Pathways Clin. Lymphoma Myeloma Leuk. 2018 18 311 320 10.1016/j.clml.2018.03.007 29606369
29. Zhang Q. Lenardo M.J. Baltimore D. 30 Years of NF-kB: A Blossoming of Relevance to Human Pathobiology Cell 2017 168 37 57 10.1016/j.cell.2016.12.012 28086098 PMC5268070
30. Shih V.F.S. Tsui R. Caldwell A. Hoffmann A. A single NFκB system for both canonical and non-canonical signaling Cell Res. 2011 21 86 102 10.1038/cr.2010.161 21102550 PMC3193412
31. Xia Y. Shen S. Verma I.M. NF-κB, an active player in human cancers Cancer Immunol. Res. 2014 2 823 830 10.1158/2326-6066.CIR-14-0112 25187272 PMC4155602
32. Li Y. Cheng H.S. Chng W.J. Tergaonkar V. Cleaver J.E. Activation of mutant TERT promoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas Proc. Natl. Acad. Sci. USA 2016 113 14402 14407 10.1073/pnas.1611106113 27911794 PMC5167176
33. Akincilar S.C. Low K.C. Liu C.Y. Yan T.D. Oji A. Ikawa M. Li S. Tergaonkar V. Quantitative assessment of telomerase components in cancer cell lines FEBS Lett. 2015 589 974 984 10.1016/j.febslet.2015.02.035 25749370
34. Khattar E. Maung K.Z.Y. Chew C.L. Ghosh A. Mok M.M.H. Lee P. Zhang J. Chor W.H.J. Cildir G. Wang C.Q. Rap1 regulates hematopoietic stem cell survival and affects oncogenesis and response to chemotherapy Nat. Commun. 2019 10 1 14 10.1038/s41467-019-13082-9 31836706 PMC6911077
35. Ozturk M.B. Li Y. Tergaonkar V. Current insights to regulation and role of telomerase in human diseases Antioxidants 2017 6 17 10.3390/antiox6010017 28264499 PMC5384180
36. Cildir G. Pant H. Lopez A.F. Tergaonkar V. The transcriptional program, functional heterogeneity, and clinical targeting of mast cells J. Exp. Med. 2017 214 2491 2506 10.1084/jem.20170910 28811324 PMC5584128
37. Siveen K.S. Nguyen A.H. Lee J.H. Li F. Singh S.S. Kumar A.P. Low G. Jha S. Tergaonkar V. Ahn K. Negative regulation of signal transducer and activator of transcription-3 signalling cascade by lupeol inhibits growth and induces apoptosis in hepatocellular carcinoma cells Br. J. Cancer 2014 111 1327 1337 10.1038/bjc.2014.422 25101566 PMC4183851
38. Chen D. Frezza M. Schmitt S. Kanwar J. Dou Q.P. Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives Curr. Cancer Drug Targets 2011 11 239 253 10.2174/156800911794519752 21247388 PMC3306611
39. Auphan N. DiDonato J.A. Rosette C. Helmberg A. Karin M. Immunosuppression by glucocorticoids: Inhibition of NF-κB activity through induction of IκB synthesis Science 1995 270 286 290 10.1126/science.270.5234.286 7569976
40. Oh K.-S. Gottschalk R.A. Lounsbury N.W. Sun J. Dorrington M. Baek S. Sun G. Wang Z. Krauss K.S. Milner J.D. Dual Roles for Ikaros in Regulation of Macrophage Chromatin State and Inflammatory Gene Expression J. Immunol. 2018 201 757 771 10.4049/jimmunol.1800158 29898962 PMC6069956
41. Krönke J. Udeshi N.D. Narla A. Grauman P. Hurst S.N. McConkey M. Svinkina T. Heckl D. Comer E. Li X. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells Science 2014 343 301 305 10.1126/science.1244851 24292625 PMC4077049
42. Lu G. Middleton R.E. Sun H. Naniong M. Ott C.J. Mitsiades C.S. Wong K.-K. Bradner J.E. Kaelin W.G. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of ikaros proteins Science 2014 343 305 309 10.1126/science.1244917 24292623 PMC4070318
43. Shannon E. Sandoval F. Greig N. Stagg P. Lenalidomide alone or lenalidomide plus dexamethasone significantly inhibit IgG and IgM in vitro⋯A possible explanation for their mechanism of action in treating multiple myeloma Int. Immunopharmacol. 2012 12 441 446 10.1016/j.intimp.2011.12.023 22245427 PMC4978999
44. Moreaux J. Legouffe E. Jourdan E. Quittet P. Rème T. Lugagne C. Moine P. Rossi J.-F. Klein B. Tarte K. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone Blood 2004 103 3148 3157 10.1182/blood-2003-06-1984 15070697 PMC2387243
45. Tai Y.T. Li X.F. Breitkreutz I. Song W. Neri P. Catley L. Podar K. Hideshima T. Chauhan D. Raje N. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment Cancer Res. 2006 66 6675 6682 10.1158/0008-5472.CAN-06-0190 16818641
46. Mondello P. Cuzzocrea S. Navarra M. Mian M. Bone marrow micro-environment is a crucial player for myelomagenesis and disease progression Oncotarget 2017 8 20394 20409 10.18632/oncotarget.14610 28099912 PMC5386771
47. Pinzone J.J. Hall B.M. Thudi N.K. Vonau M. Qiang Y.-W. Rosol T.J. Shaughnessy J.D. The role of Dickkopf-1 in bone development, homeostasis, and disease Blood 2009 113 517 525 10.1182/blood-2008-03-145169 18687985 PMC2628360
48. Hata H. Bone lesions and macrophage inflammatory protein-1 alpha (MIP-1α) in human multiple myeloma Leuk. Lymphoma 2005 46 967 972 10.1080/10428190500066636 16019547
49. Chng W.J. Glebov O. Bergsagel P.L. Kuehl W.M. Genetic events in the pathogenesis of multiple myeloma Best Pract. Res. Clin. Haematol. 2007 20 571 596 10.1016/j.beha.2007.08.004 18070707 PMC2198931
50. de Weers M. Tai Y.-T. van der Veer M.S. Bakker J.M. Vink T. Jacobs D.C.H. Oomen L.A. Peipp M. Valerius T. Slootstra J.W. Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors J. Immunol. 2011 186 1840 1848 10.4049/jimmunol.1003032 21187443
51. Kaku H. Horikawa K. Obata Y. Kato I. Okamoto H. Sakaguchi N. Gerondakis S. Takatsu K. NF-kB is required for CD38-mediated induction of Cg1 germline transcripts in murine B. lymphocytes Int. Immunol. 2002 14 1055 1064 10.1093/intimm/dxf072 12202402
52. Qian Y. Chen C. Ma L. Wang Z. Wang L.-F. Zuo L. Yang Y. Huang X. Jiang M. Wang X. CD38 Deficiency Promotes Inflammatory Response Through Activating Sirt1/NF-κB-Mediated Inhibition of TLR2 Expression in Macrophages Mediat. Inflamm. 2018 2018 1 13 10.1155/2018/8736949 PMC6011090 29977153
53. Neri P. Kumar S. Fulciniti M.T. Vallet S. Chhetri S. Mukherjee S. Tai Y. Chauhan D. Tassone P. Venuta S. Neutralizing B-cell-activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model Clin. Cancer Res. 2007 13 5903 5909 10.1158/1078-0432.CCR-07-0753 17908986
54. Blimark C. Holmberg E. Mellqvist U.H. Landgren O. Björkholm M. Hultcrantz M. Kjellander C. Turesson I. Kristinsson S.Y. Multiple myeloma and infections: A population-based study on 9253 multiple myeloma patients Haematologica 2015 100 107 113 10.3324/haematol.2014.107714 25344526 PMC4281323
55. Nucci M. Anaissie E. Infections in Patients with Multiple Myeloma in the Era of High-Dose Therapy and Novel Agents Clin. Infect. Dis. 2009 49 1211 1225 10.1086/605664 19769539
56. Teh B.W. Harrison S.J. Worth L.J. Thursky K.A. Slavin M.A. Infection risk with immunomodulatory and proteasome inhibitor–based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysis Eur. J. Cancer 2016 67 21 37 10.1016/j.ejca.2016.07.025 27592069
57. Li J. Li Y. Huang B. Zheng D. Chen M. Zhou Z. Drug-Induced Modulation of T Lymphocytes as a Potential Mechanism of Susceptibility to Infections in Patients with Multiple Myeloma During Bortezomib Therapy Cell Biochem. Biophys. 2014 71 457 464 10.1007/s12013-014-0224-x 25343940 PMC4289524
58. Offidani M. Corvatta L. Bringhen S. Gentili S. Gay F. Maracci L. Boccadoro M. Leoni P. Palumbo A. Infection Complications in 476 Patients with Newly Diagnosed Multiple Myeloma Treated with Lenalidomide or Bortezomib Combinations Blood 2015 126 5365 10.1182/blood.V126.23.5365.5365
59. Prescott J. Cook S. Targeting IKKβ in Cancer: Challenges and Opportunities for the Therapeutic Utilisation of IKKβ Inhibitors Cells 2018 7 115 10.3390/cells7090115 PMC6162708 30142927
60. Goldstein D.A. Denosumab for bone lesions in multiple myeloma—What is its value? Haematologica 2018 103 753 754 10.3324/haematol.2017.185264 29712820 PMC5927995
61. Taniguchi K. Karin M. NF-B, inflammation, immunity and cancer: Coming of age Nat. Rev. Immunol. 2018 18 309 324 10.1038/nri.2017.142 29379212
62. Ben-Neriah Y. Karin M. Inflammation meets cancer, with NF-κB as the matchmaker Nat. Immunol. 2011 12 715 723 10.1038/ni.2060 21772280
63. Raje N.S. Moreau P. Terpos E. Benboubker L. Grząśko N. Holstein S.A. Oriol A. Huang S.-Y. Beksac M. Kuliczkowski K. Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma Br. J. Haematol. 2017 176 783 795 10.1111/bjh.14483 28005265
64. Liu J. Sudom A. Min X. Cao Z. Gao X. Ayres M. Lee F. Cao P. Johnstone S. Plotnikova O. Structure of the nuclear factor κB-inducing kinase (NIK) kinase domain reveals a constitutively active conformation J. Biol. Chem. 2012 287 27326 27334 10.1074/jbc.M112.366658 22718757 PMC3431628
65. Demchenko Y.N. Brents L.A. Li Z. Bergsagel L.P. McGee L.R. Kuehl M.W. Novel inhibitors are cytotoxic for myeloma cells with NFkB inducing kinase-dependent activation of NFkB Oncotarget 2014 5 4554 4566 10.18632/oncotarget.2128 24980832 PMC4147345
66. Rushe M. Silvian L. Bixler S. Chen L.L. Cheung A. Bowes S. Cuervo H. Berkowitz S. Zheng T. Guckian K. Structure of a NEMO/IKK-Associating Domain Reveals Architecture of the Interaction Site Structure 2008 16 798 808 10.1016/j.str.2008.02.012 18462684
67. Habineza Ndikuyeze G. Gaurnier-Hausser A. Patel R. Baldwin A.S. May M.J. Flood P. Krick E. Propert K.J. Mason N.J. A Phase I Clinical Trial of Systemically Delivered NEMO Binding Domain Peptide in Dogs with Spontaneous Activated B-Cell like Diffuse Large B-Cell Lymphoma PLoS ONE 2014 9 e95404 10.1371/journal.pone.0095404 24798348 PMC4010398
68. Xu X. Li Y. Bharath S.R. Ozturk M.B. Bowler M.W. Loo B.Z.L. Tergaonkar V. Song H. Structural basis for reactivating the mutant TERT promoter by cooperative binding of p52 and ETS1 Nat. Commun. 2018 9 3138 10.1038/s41467-018-05644-0 30093619 PMC6085347
69. Greil C. Engelhardt M. Ihorst G. Schoeller K. Bertz H. Marks R. Zeiser R. Duyster J. Einsele H. Finke J. Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life Haematologica 2019 104 370 379 10.3324/haematol.2018.200881 30237266 PMC6355495
70. Esma F. Salvini M. Troia R. Boccadoro M. Larocca A. Pautasso C. Melphalan hydrochloride for the treatment of multiple myeloma Expert Opin. Pharmacother. 2017 18 1127 1136 10.1080/14656566.2017.1349102 28658983
71. Kyle R.A. Rajkumar S.V. Multiple myeloma Blood 2008 111 2962 2972 10.1182/blood-2007-10-078022 18332230 PMC2265446
72. Chari A. Vogl D.T. Gavriatopoulou M. Nooka A.K. Yee A.J. Huff C.A. Moreau P. Dingli D. Cole C. Lonial S. Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma N. Engl. J. Med. 2019 381 727 738 10.1056/NEJMoa1903455 31433920
73. Bahlis N.J. Sutherland H. White D. Sebag M. Lentzsch S. Kotb R. Venner C.P. Gasparetto C. Del Col A. Neri P. Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma Blood 2018 132 2546 2554 10.1182/blood-2018-06-858852 30352784 PMC6302280
74. Van Rhee F. Szmania S.M. Dillon M. Van Abbema A.M. Li X. Stone M.K. Garg T.K. Shi J. Moreno-Bost A.M. Yun R. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma Mol. Cancer Ther. 2009 8 2616 2624 10.1158/1535-7163.MCT-09-0483 19723891 PMC2748787
75. Cho S.F. Anderson K.C. Tai Y.T. Targeting B cell maturation antigen (BCMA) in multiple myeloma: Potential uses of BCMA-based immunotherapy Front. Immunol. 2018 9 1821 10.3389/fimmu.2018.01821 30147690 PMC6095983
76. Raje N. Berdeja J. Lin Y. Siegel D.S. Jagannath S. Madduri D. Liedtke M. Rosenblatt J. Maus M.V. Turka A. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma N. Engl. J. Med. 2019 380 1726 1737 10.1056/NEJMoa1817226 31042825 PMC8202968
77. Drent E. Themeli M. Poels R. De Jong-Korlaar R. Yuan H. De Bruijn J. Martens A.C. Zweegman S. Van De Donk N.W. Groen R. A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization Mol. Ther. 2017 25 1946 1958 10.1016/j.ymthe.2017.04.024 28506593 PMC5542711
78. Chu J. He S. Deng Y. Zhang J. Peng Y. Hughes T. Yi L. Kwon C.-H. Wang Q.-E. Devine S.M. Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells Clin. Cancer Res. 2014 20 3989 4000 10.1158/1078-0432.CCR-13-2510 24677374 PMC4119545
79. D’Agostino M. Raje N. Anti-BCMA CAR T-cell therapy in multiple myeloma: Can we do better? Leukemia 2020 34 21 34 10.1038/s41375-019-0669-4 31780814
80. Jelinek T. Hajek R. PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future Oncoimmunology 2016 5 e1254856 10.1080/2162402X.2016.1254856 28123899 PMC5215080
81. Gowrishankar K. Gunatilake D. Gallagher S.J. Tiffen J. Rizos H. Hersey P. Inducible but Not Constitutive Expression of PD-L1 in Human Melanoma Cells Is Dependent on Activation of NF-κB PLoS ONE 2015 10 e0123410 10.1371/journal.pone.0123410 25844720 PMC4386825
82. Blaquiere N. Castanedo G.M. Burch J.D. Berezhkovskiy L.M. Brightbill H. Brown S. Chan C. Chiang P.C. Crawford J.J. Dong T. Scaffold-Hopping Approach to Discover Potent, Selective, and Efficacious Inhibitors of NF-ÎB Inducing Kinase J. Med. Chem. 2018 61 6801 6813 29940120 10.1021/acs.jmedchem.8b00678
83. Cheng G. Mei X.B. Yan Y. Chen J. Zhang B. Li J. Dong X. Lin N. Zhou Y. Identification of new NIK inhibitors by discriminatory analysis-based molecular docking and biological evaluation Arch. Pharm. (Weinheim) 2019 352 e1800374 10.1002/ardp.201800374 31116887
84. Takakura N. Matsuda M. Khan M. Hiura F. Aoki K. Hirohashi Y. Mori K. Yasuda H. Hirata M. Kitamura C. A novel inhibitor of NF-κB-inducing kinase prevents bone loss by inhibiting osteoclastic bone resorption in ovariectomized mice Bone 2020 135 115316 10.1016/j.bone.2020.115316 32169603
85. Li Z. Li X. Su M.-B. Gao L.-X. Zhou Y.-B. Yuan B. Lyu X. Yan Z. Hu C. Zhang H. Discovery of a Potent and Selective NF-κB-Inducing Kinase (NIK) Inhibitor That Has Anti-inflammatory Effects in Vitro and in Vivo J. Med. Chem. 2020 63 4388 4407 32216342 10.1021/acs.jmedchem.0c00396
86. Fulciniti M. Tassone P. Hideshima T. Vallet S. Nanjappa P. Ettenberg S.A. Shen Z. Patel N. Tai Y. Chauhan D. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma Blood 2009 114 371 379 10.1182/blood-2008-11-191577 19417213 PMC2714212
87. Bianchi G. Oliva L. Cascio P. Pengo N. Fontana F. Cerruti F. Orsi A. Pasqualetto E. Mezghrani A. Calbi V. The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition Blood 2009 113 3040 3049 10.1182/blood-2008-08-172734 19164601
88. Scott K. Hayden P.J. Will A. Wheatley K. Coyne I. Bortezomib for the treatment of multiple myeloma Cochrane Database Syst. Rev. 2016 4 CD010816 10.1002/14651858.CD010816.pub2 27096326 PMC10387344
89. Chari A. Richardson P.G. Romanus D. Dimopoulos M.A. Sonneveld P. Terpos E. Hajek R. Raju A. Palumbo A. Cain L.E. Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): A comparison of VRd, KRd, and IRd Expert Rev. Hematol. 2020 13 421 433 10.1080/17474086.2020.1729734 32148109
90. Dimopoulos M. Siegel D. White D.J. Boccia R. Iskander K.S. Yang Z. Kimball A.S. Mezzi K. Ludwig H. Niesvizky R. Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: A subgroup analysis of ENDEAVOR Blood 2019 133 147 155 10.1182/blood-2018-06-860015 30478094 PMC6346374
91. Dimopoulos M.A. Goldschmidt H. Niesvizky R. Joshua D. Chng W.-J. Oriol A. Orlowski R.Z. Ludwig H. Facon T. Hájek R. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): An interim overall survival analysis of an open-label, randomised, phase 3 trial Lancet Oncol. 2017 18 1327 1337 10.1016/S1470-2045(17)30578-8 28843768
92. van de Donk N.W. Carfilzomib versus bortezomib: No longer an ENDEAVOR Lancet Oncol. 2017 18 1288 1290 10.1016/S1470-2045(17)30613-7 28843767
93. Siegel D.S. Dimopoulos M.A. Ludwig H. Facon T. Goldschmidt H. Jakubowiak A. San-Miguel J. Obreja M. Blaedel J. Stewart A.K. Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma J. Clin. Oncol. 2018 36 728 734 10.1200/JCO.2017.76.5032 29341834
94. Shin E.M. Neja S.A. Fidan K. Chua J.Y.H. Chung T. Bertin N. Tergaonkar V. Chng W. Ooi M.G. Lymphocyte cytosolic protein 1 (LCP1) is a novel TRAF3 dysregulation biomarker with potential prognostic value in multiple myeloma Genome Instab. Dis. 2020 10.1007/s42764-020-00014-x
95. Zarnegar B.J. Wang Y. Mahoney D.J. Dempsey P.W. Cheung H.H. He J. Shiba T. Yang X. Yeh W.C. Mak T.W. Noncanonical NF-κB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK Nat. Immunol. 2008 9 1371 1378 10.1038/ni.1676 18997794 PMC2676931
96. Vallabhapurapu S. Matsuzawa A. Zhang W.Z. Tseng P.H. Keats J.J. Wang H. Vignali D.A.A. Bergsagel P.L. Karin M. Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-κB signaling Nat. Immunol. 2008 9 1364 1370 10.1038/ni.1678 18997792 PMC2671996
97. Lin W.W. Yi Z. Stunz L.L. Maine C.J. Sherman L.A. Bishop G.A. The adaptor protein TRAF3 inhibits interleukin-6 receptor signaling in B cells to limit plasma cell development Sci. Signal. 2015 8 ra88 10.1126/scisignal.aaa5157 26329582 PMC4720969
98. Mambetsariev N. Lin W.W. Wallis A.M. Stunz L.L. Bishop G.A. TRAF3 deficiency promotes metabolic reprogramming in B cells Sci. Rep. 2016 6 1 9 10.1038/srep35349 27752131 PMC5082756
99. Mambetsarieva N. Lin W.W. Stunza L.L. Hansona B.M. Hildebranda J.M. Bishop G.A. Nuclear TRAF3 is a negative regulator of CREB in B cells Proc. Natl. Acad. Sci. USA 2016 113 1032 1037 10.1073/pnas.1514586113 26755589 PMC4743771
100. Xie P. Stunz L.L. Larison K.D. Yang B. Bishop G.A. Tumor Necrosis Factor Receptor-Associated Factor 3 Is a Critical Regulator of B Cell Homeostasis in Secondary Lymphoid Organs Immunity 2007 27 253 267 10.1016/j.immuni.2007.07.012 17723217 PMC2084086
101. Ma T. Sadashivaiah K. Chellaiah M.A. Regulation of sealing ring formation by L-plastin and cortactin in osteoclasts J. Biol. Chem. 2010 285 29911 29924 10.1074/jbc.M109.099697 20650888 PMC2943304
102. Chellaiah M.A. Majumdar S. Aljohani H. Peptidomimetic inhibitors of L-plastin reduce the resorptive activity of osteoclast but not the bone forming activity of osteoblasts in vitro PLoS ONE 2018 13 e0204209 10.1371/journal.pone.0204209 30248139 PMC6152981
103. Tiedemann K. Sadvakassova G. Mikolajewicz N. Juhas M. Sabirova Z. Tabariès S. Gettemans J. Siegel P.M. Komarova S.V. Exosomal Release of L-Plastin by Breast Cancer Cells Facilitates Metastatic Bone Osteolysis Transl. Oncol. 2019 12 462 474 10.1016/j.tranon.2018.11.014 30583289 PMC6305809
104. Klemke M. Rafael M.T. Wabnitz G.H. Weschenfelder T. Konstandin M.H. Garbi N. Autschbach F. Hartschuh W. Samstag Y. Phosphorylation of ectopically expressed L-plastin enhances invasiveness of human melanoma cells Int. J. Cancer 2007 120 2590 2599 10.1002/ijc.22589 17290393
105. Dun M.D. Chalkley R.J. Faulkner S. Keene S. Avery-Kiejda K.A. Scott R.J. Falkenby L.S. Cairns M.J. Larsen M.R. Bradshaw L.A. Proteotranscriptomic profiling of 231-BR breast cancer cells: Identification of potential biomarkers and therapeutic targets for brain metastasis Mol. Cell. Proteom. 2015 14 2316 2330 10.1074/mcp.M114.046110 26041846 PMC4563718
106. Inaguma S. Riku M. Ito H. Tsunoda T. Ikeda H. Kasai K. GLI1 orchestrates CXCR4/CXCR7 signaling to enhance migration and metastasis of breast cancer cells Oncotarget 2015 6 33648 33657 10.18632/oncotarget.5203 26413813 PMC4741792
107. Otsuka M. Kato M. Yoshikawa T. Chen H. Brown E.J. Masuho Y. Omata M. Seki N. Differential expression of the L-plastin gene in human colorectal cancer progression and metastasis Biochem. Biophys. Res. Commun. 2001 289 876 881 10.1006/bbrc.2001.6047 11735128
108. Foran E. McWilliam P. Kelleher D. Croke D.T. Long A. The leukocyte protein L-plastin induces proliferation, invasion and loss of E-cadherin expression in colon cancer cells Int. J. Cancer 2006 118 2098 2104 10.1002/ijc.21593 16287074
109. Ning Y. Gerger A. Zhang W. Hanna D.L. Yang D. Winder T. Wakatsuki T. Labonte M.J. Stintzing S. Volz N. Plastin polymorphisms predict gender- and stage-specific colon cancer recurrence after adjuvant chemotherapy Mol. Cancer Ther. 2014 13 528 539 10.1158/1535-7163.MCT-13-0646 24170770 PMC3945969
110. Fang Z.-Q. Zang W.-D. Chen R. Ye B. Wang X. Yi S. Chen W. He F. Ye G. Gene expression profile and enrichment pathways in different stages of bladder cancer Genet. Mol. Res. 2013 12 1479 1489 10.4238/2013.May.6.1 23765955
111. Kim D.S. Choi Y.D. Moon M. Kang S. Lim J.B. Kim K.Y. Park K.M. Cho N.H. Composite three-marker assay for early detection of kidney cancer Cancer Epidemiol. Biomark. Prev. 2013 22 390 398 10.1158/1055-9965.EPI-12-1156 23479363
112. Dubovsky J.A. Chappell D.L. Harrington B.K. Agrawal K. Andritsos L.A. Flynn J.M. Jones J.A. Paulaitis M.E. Bolon B. Johnson A.J. Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing Blood 2013 122 3308 3316 10.1182/blood-2013-05-504597 24009233 PMC3953089
113. Freudenmann L.K. Mayer C. Rodemann H.P. Dittmann K. Reduced exosomal L-Plastin is responsible for radiation-induced bystander effect Exp. Cell Res. 2019 383 111498 10.1016/j.yexcr.2019.111498 31302031
114. Bosseler M. Marani V. Broukou A. Lequeux A. Kaoma T. Schlesser V. François J.H. Palissot V. Berchem G.J. Aouali N. Inhibition of HIF1α-dependent upregulation of phospho-L-Plastin resensitizes multiple myeloma cells to frontline therapy Int. J. Mol. Sci. 2018 19 1551 10.3390/ijms19061551 29882856 PMC6032243
115. Majumdar S. Wadajkar A.S. Aljohani H. Reynolds M.A. Kim A.J. Chellaiah M. Engineering of L-Plastin Peptide-Loaded Biodegradable Nanoparticles for Sustained Delivery and Suppression of Osteoclast Function In Vitro Int. J. Cell Biol. 2019 2019 6943986 10.1155/2019/6943986 31191656 PMC6525930
116. Shinohara H. Yasuda T. Aiba Y. Sanjo H. Hamadate M. Watarai H. Sakurai H. Kurosaki T. PKCβ regulates BCR-mediated IKK activation by facilitating the interaction between TAK1 and CARMA1 J. Exp. Med. 2005 202 1423 1431 10.1084/jem.20051591 16301747 PMC2212994
117. Stadanlick J.E. Kaileh M. Karnell F.G. Scholz J.L. Miller J.P. Quinn W.J. Brezski R.J. Treml L.S. Jordan K.A. Monroe J.G. Tonic B cell antigen receptor signals supply an NF-κB substrate for prosurvival BLyS signaling Nat. Immunol. 2008 9 1379 1387 10.1038/ni.1666 18978795 PMC2744141
118. Shinzawa M. Konno H. Qin J. Akiyama N. Miyauchi M. Ohashi H. Miyamoto-Sato H. Yanagawa H. Akiyama T. Inoue J.-i. Catalytic subunits of the phosphatase calcineurin interact with NF-κB-inducing kinase (NIK) and attenuate NIK-dependent gene expression Sci. Rep. 2015 5 10758 10.1038/srep10758 26029823 PMC5377069
119. Wicker L.S. Boltz R.C. Matt V. Nichols E.A. Peterson L.B. Sigal N.H. Suppression of B cell activation by cyclosporin A, FK506 and rapamycin Eur. J. Immunol. 1990 20 2277 2283 10.1002/eji.1830201017 1700753
120. Tan D. Chng W.J. Chou T. Nawarawong W. Hwang S.Y. Chim C.S. Chen W. Durie B.G.M. Lee J.H. Management of multiple myeloma in Asia: Resource-stratified guidelines Lancet Oncol. 2013 14 e571 e581 10.1016/S1470-2045(13)70404-2 24176575
121. Fonseca R. Bergsagel P.L. Drach J. Shaughnessy J. Gutierrez N. Stewart A.K. Morgan G. Van Ness B. Chesi M. Minvielle S. International Myeloma Working Group molecular classification of multiple myeloma: Spotlight review Leukemia 2009 23 2210 2221 10.1038/leu.2009.174 19798094 PMC2964268
122. Varga G. Mikala G. Andrikovics H. Koszarska M. Balassa K. Ádám E. Kozma A. Tordai A. Masszi T. NFKB1 -94ins/delATTG polymorphism is a novel prognostic marker in first line-treated multiple myeloma Br. J. Haematol. 2015 168 679 688 10.1111/bjh.13197 25363231
123. Kumar S. Kaufman J.L. Gasparetto C. Mikhael J. Vig R. Pegouri B. Benboubker R. Facon T. Amiot M. Moreau P. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma Blood 2017 130 2401 2409 10.1182/blood-2017-06-788786 29018077
124. Martinez-Garcia E. Popovic R. Min D.J. Sweet S.M.M. Thomas P.M. Zamdborg L. Heffner A. Will C. Lamy L. Staudt L.M. The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t (4;14) multiple myeloma cells Blood 2011 117 211 220 10.1182/blood-2010-07-298349 20974671 PMC3037745
125. Coussens N.P. Kales S.C. Henderson M.J. Lee O.W. Horiuchi K.Y. Wang Y. Chen Q. Kuznetsova E. Wu J. Chakka S. High-throughput screening with nucleosome substrate identifies small-molecule inhibitors of the human histone lysine methyltransferase NSD2 J. Biol. Chem. 2018 293 13750 13765 10.1074/jbc.RA118.004274 29945974 PMC6120216
126. Brighton T.A. Khot A. Harrison S.J. Ghez D. Weiss B.M. Kirsch A. Magen H. Gironella M. Oriol A. Streetly M. Randomized, double-blind, placebo-controlled, multicenter study of siltuximab in high-risk smoldering multiple myeloma Clin. Cancer Res. 2019 25 3772 3775 10.1158/1078-0432.CCR-18-3470 30890552
127. Jonsson B. Nilsson K. Nygren P. Larsson R. SDZ PSC-833—A novel potent in vitro chemosensitizer in multiple myeloma Anticancer Drugs 1992 3 641 646 10.1097/00001813-199212000-00013 1363199
128. Friedenberg W.R. Rue M. Blood E.A. Dalton W.S. Shustik C. Larson R.A. Sonneveld P. Greipp P.R. Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): A trial of the Eastern Cooperative Oncology Group Cancer 2006 106 830 838 10.1002/cncr.21666 16419071
129. Fassmannová D. Sedlák F. Sedláček J. Špička I. Grantz Šašková K. Nelfinavir Inhibits the TCF11/Nrf1-Mediated Proteasome Recovery Pathway in Multiple Myeloma Cancers 2020 12 1065 10.3390/cancers12051065 PMC7281108 32344880
130. Reddi D.M. Lu C.M. Fedoriw G. Liu Y. Wang F.F. Ely S. Boswell E.L. Louissaint A. Arcasoy M.O. Goodman B.K. Myeloid neoplasms secondary to plasma cell myeloma: An intrinsic predisposition or therapy-related phenomenon? A clinicopathologic study of 41 cases and correlation of cytogenetic features with treatment regimens Am. J. Clin. Pathol. 2012 138 855 866 10.1309/AJCPOP7APGDT9JIU 23161720
131. Klimek V.M. Recent advances in the management of therapy-related myelodysplastic syndromes and acute myeloid leukemia Curr. Opin. Hematol. 2013 20 137 143 10.1097/MOH.0b013e32835d82e6 23343830
132. Pemmaraju N. Shah D. Kantarjian H. Orlowski R.Z. Nogueras González G.M. Baladanayuthapani V. Jain N. Wagner V. Garcia-Manero G. Shah J. Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia Clin. Lymphoma Myeloma Leuk. 2015 15 110 114 10.1016/j.clml.2014.07.001 25107338 PMC4294996
133. Fernández-Caballero M. Salmerón D. Dolores Chirlaque M. Chen-Liang T.H. Hurtado A.M. García Malo M.D. Ortuño F.J. Roldán V. Vicente V. Jerez A. Increasing therapy-related myeloid neoplasms in multiple myeloma Eur. J. Clin. Investig. 2018 49 e13050 10.1111/eci.13050 30422316